PERI-EDU University Education
Osteoporosis and antiresorptive exposure are related but distinct clinical variables. Osteoporosis alone does not automatically contraindicate implant treatment. Medicine indication, dose, schedule, comorbidity and long-term peri-implant inflammation can change the risk profile.
Systemic fragility and local jaw conditions
Osteoporosis is a systemic skeletal disorder characterized by reduced bone strength and increased fracture susceptibility. Diagnosis usually relies on fragility-fracture history, bone mineral density at validated skeletal sites and clinical fracture-risk assessment. These measurements do not directly describe an individual implant site.
| Domain | What it describes | Implant relevance |
|---|---|---|
| Systemic osteoporosis | Whole-skeleton fragility and future fracture risk. | Signals a medical bone disorder but does not define jaw anatomy or guarantee implant failure. |
| DXA result | Areal bone mineral density, usually at the hip and lumbar spine. | Cannot be transferred directly to a mandibular or maxillary implant site. |
| Jawbone anatomy | Available dimensions, cortical boundaries and trabecular architecture. | Guides implant position, osteotomy and augmentation planning. |
| Bone mechanics | Resistance during preparation, insertion torque and implant stability. | Provides site-specific surgical information but does not diagnose osteoporosis. |
| Bone biology | Turnover, mineralization, vascularity and cellular healing. | Influenced by age, disease, nutrition and medication. |
CBCT remains valuable for anatomy and qualitative architecture. Its grey values should not be treated as calibrated DXA measurements without a validated protocol.
Remodelling and antiresorptive treatment
Bone renews itself through coupled osteoclast resorption and osteoblast formation. Antiresorptive medicines reduce fracture risk by suppressing resorption, but their mechanisms and persistence differ.
| Therapy | Main skeletal action | Dental planning point |
|---|---|---|
| Oral bisphosphonates | Bind to mineralized bone and reduce osteoclast activity. | Record medicine, duration, adherence and indication; stopping does not rapidly remove skeletal exposure. |
| IV bisphosphonates for osteoporosis | Provide potent intermittent antiresorptive treatment. | Do not equate osteoporosis dosing with frequent high-dose oncology regimens. |
| Denosumab for osteoporosis | RANKL inhibition causes rapid and reversible suppression of osteoclast activity. | Unplanned delay or cessation can cause rebound bone loss and vertebral fractures. |
| Romosozumab | Inhibits sclerostin, increasing formation and reducing resorption. | Review the cardiovascular and bone-treatment context. |
| Anabolic therapy | Stimulates bone formation through PTH-receptor or related pathways. | Treatment sequencing remains a specialist decision. |
Antiresorptive therapy prevents serious fragility fractures. The rare possibility of MRONJ should not lead patients to abandon treatment without medical guidance.
What implant survival evidence shows
Recent systematic reviews generally report similar implant survival in patients with osteoporosis and controls. Reviews of osteoporosis-dose antiresorptive treatment also do not show a consistent increase in implant failure. Confidence remains limited by observational study designs and relatively sparse long-term drug-specific data.
- Osteoporosis alone has not produced a consistent reduction in implant survival.
- Pooled analyses generally do not show a clinically important increase in marginal bone loss.
- Evidence concerning low-dose bisphosphonates is comparatively reassuring.
- Data for osteoporosis-dose denosumab are more limited but do not justify automatic exclusion.
- Evidence from osteoporosis treatment must not be extrapolated to high-dose oncology regimens.
Reassuring average survival supports individualized treatment rather than automatic eligibility. A functioning implant may still develop peri-implant inflammation, marginal bone loss or a rare medication-related complication.
Primary stability and surgical adaptation
Systemic osteoporosis does not provide a direct map of jawbone density. Local cortical thickness, trabecular structure, implant geometry and osteotomy technique determine primary stability.
| Finding | Possible adaptation | Boundary |
|---|---|---|
| Thin cortex or low resistance | Adapt implant geometry and osteotomy preparation. | High insertion torque is not a substitute for viable bone. |
| Limited ridge dimensions | Consider shorter or narrower implants, augmentation or staged treatment. | Do not increase surgical burden automatically. |
| Low initial stability | Use a protected healing period and delay loading when indicated. | One stability value cannot guarantee osseointegration. |
| Need for augmentation | Compare regenerative benefit with additional trauma and healing demand. | Evidence during antiresorptive therapy remains limited. |
| Periodontal disease | Stabilize infection and establish maintainable hygiene first. | Systemic treatment cannot compensate for local inflammation. |
Aggressive osteotomy undersizing or excessive insertion torque can impair perfusion and produce microdamage. The objective is adequate stability while preserving bone vitality.
Osteoporosis-dose therapy and MRONJ
MRONJ remains rare during osteoporosis treatment and its absolute risk is far lower than during high-dose oncology regimens. Nevertheless, implant surgery causes osseous injury and a functioning implant can later become a site of inflammation.
| Risk dimension | Lower-concern pattern | Higher-concern pattern |
|---|---|---|
| Indication | Osteoporosis or low bone mass. | Metastatic bone disease or another malignant indication. |
| Dose and schedule | Standard osteoporosis regimen. | Frequent high-dose parenteral oncology regimen. |
| Local tissue | Healthy mucosa, controlled periodontium and cleanable prosthesis. | Active periodontitis, suppuration or mucosal trauma. |
| Additional treatment | No major immunosuppression. | Corticosteroids, chemotherapy or antiangiogenic therapy. |
| Procedure | Straightforward placement with limited trauma. | Extensive augmentation or repeated bone surgery. |
CTX and other bone turnover markers do not predict individual MRONJ risk sufficiently for implant clearance. Evidence is also insufficient to recommend routine antiresorptive drug interruption. Denosumab timing requires particular caution because delayed treatment can cause rebound vertebral fractures.
Early surgical and late implant-associated complications
Implant-associated MRONJ can develop shortly after surgery or years after successful osseointegration.
- Surgery-triggered presentation: non-healing wound, exposed or probeable bone, pain or infection after implant placement or augmentation.
- Presence-associated presentation: inflammation, sequestration or exposed bone around a previously integrated implant.
- Routine peri-implantitis: biofilm-associated inflammation with progressive supporting-bone loss.
- Mechanical failure: overload, fracture or loss of osseointegration without diagnostic MRONJ features.
Persistent exposed bone, pain, suppuration, paraesthesia, fistula or failure of expected healing requires early specialist assessment. Percentages reported in selected MRONJ case series cannot be interpreted as population incidence.
Augmentation, prosthetic design and maintenance
Straightforward implant survival data do not prove the safety of every regenerative procedure. Bone grafting, membrane exposure and repeated surgery add tissue trauma and infection opportunity.
- Control periodontal, periapical and peri-implant infection before surgery.
- Compare the benefit of augmentation with alternatives that reduce surgical burden.
- Use a prosthetic design that permits effective home care and professional maintenance.
- Review early healing for wound dehiscence, infection and abnormal tissue response.
- Monitor probing findings, suppuration and radiographic changes against baseline.
Successful early osseointegration does not end risk assessment. Antiresorptive treatment can begin after implant placement, and late inflammation can change the local environment.
A decision pathway
- Confirm osteoporosis context: record diagnosis, fracture history, DXA context and secondary causes.
- Reconcile medicines: record agent, indication, route, dose, schedule, duration and last dose.
- Assess local readiness: evaluate periodontal health, infection, anatomy, hygiene and prosthetic access.
- Match procedure burden: define the number of implants, augmentation and loading strategy.
- Discuss benefits and uncertainty: explain alternatives, evidence limitations and low but non-zero MRONJ risk.
- Plan surveillance: establish baseline documentation, early healing checks and long-term maintenance.
Clinical synthesis
- Separate systemic osteoporosis from local implant-site anatomy.
- Do not use hip or spine DXA values as direct measurements of jawbone.
- Osteoporosis alone generally does not reduce implant survival in current meta-analyses.
- Interpret antiresorptive therapy by indication, dose, route, schedule and duration.
- Do not extrapolate osteoporosis-dose evidence to high-dose oncology treatment.
- Never advise unsupervised discontinuation of bisphosphonates or denosumab.
- Do not use CTX as an MRONJ clearance test.
- Maintain long-term surveillance for late inflammation and abnormal healing.
Download the full educational material
The full PDF expands osteoporosis assessment, bone-remodelling therapies, implant survival evidence, surgical adaptation, MRONJ pathways and long-term maintenance.
Download the full educational material (PDF)
Selected references
- Kim SY, et al. Impact of Osteoporosis on Dental Implant Survival, Failure, and Marginal Bone Loss. J Clin Med. 2025;14:6719.
- Lemos CAA, et al. Dental implants in patients with osteoporosis: systematic review and meta-analysis. Clin Oral Investig. 2023.
- Ali DS, et al. Antiresorptive Therapy and Dental Implant Outcomes in Patients With Osteoporosis. Endocr Pract. 2025.
- Mirza R, et al. Dental Implant Failure and MRONJ in Patients Receiving Antiresorptive Therapy for Osteoporosis. Endocr Pract. 2025.
- Ruggiero SL, et al. AAOMS Position Paper on MRONJ – 2022 Update. J Oral Maxillofac Surg. 2022;80:920-943.
- Stavropoulos A, et al. Effect of antiresorptive drugs on implant therapy. Clin Oral Implants Res. 2018;29 Suppl 18:54-92.
Explore related PERI-EDU resources
#UniversityEducation #OnlineCourses #ClinicalCases #PERIEDU #Osteoporosis #AntiresorptiveTherapy #ImplantStability #MRONJ
This material supports implant risk assessment and interdisciplinary communication. It does not replace osteoporosis diagnosis, fracture-risk treatment, specialist MRONJ management or individualized medical care.
This work was co-funded by the European Union under grant agreement No. 2024-1-PL01-KA220-HED-000251208. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the Foundation for the Development of the Education System (FRSE). Neither the European Union nor FRSE can be held responsible for them.